Angiotensin II for the emergency physician. Issue 11 (19th February 2020)

• Record Type: Journal Article
• Authors: Wallis, Marianne C; Chow, Jonathan H; Winters, Michael E; McCurdy, Michael T
• Is Part Of: Emergency medicine journal. Volume 37:Issue 11(2020)
• Page Start: 717
• Page End: 721
• Publication Date: 2020-02-19
• Subjects: clincial management -- intensive care -- resuscitation; Emergency medicine -- Periodicals; 616.02505
• DOI: 10.1136/emermed-2019-209062
• Languages: English
• ISSNs: 1472-0205

Abstract

Abstract : Refractory hypotension is one of the most common and difficult clinical problems faced by acute care clinicians, and it poses a particularly large problem to the emergency physician when a patient in undifferentiated shock arrives in the department. Angiotensin II (Ang-2) has been previously used as a vasopressor to combat shock; the feasibility of its clinical use has been reinvigorated after approval of a human synthetic formulation of the medication by the US Food and Drug Administration in 2017 and the European Medicines Agency in 2019. A thorough literature search was completed, and in this review, we discuss the discovery and development of Ang-2, its complex mechanisms of vasoconstriction, its potential adverse effects and its potential role in clinical practice for emergency physicians.